(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 29 September 2005 (29.09.2005)

PCT

(10) International Publication Number WO 2005/089045 A2

(51) International Patent Classification: Not classified

(21) International Application Number:

PCT/IB2005/002063

(22) International Filing Date: 18 March 2005 (18.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/554,859 19 March 2004 (19.03.2004) U

- (71) Applicants (for all designated States except US): UNI-VERSITE CATHOLIQUE DE LOUVAIN [BE/BE]; Avenue Hippocrate 10/1756-1200, B-1200 Bruxelles (BE). CLINIQUE UNIVERSITAIRES SAINT-LUC [BE/BE]; Avenue Hippocrate 10/1756-1200, B-1200 Bruxelles (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KETELSLEGERS, Jean-Marie [BE/BE]; Avenue Hippocrate 10/1756-1200,


B-1200 Bruxelles (BE). **ROUSSEAU, Michel** [BE/BE]; Avenue Hippocrate 10/1756-1200, B-1200 Bruxelles (BE).

- (74) Agent: SPORATEC & VIVES; CEI-Chemin du Cyclotron, 6, B-1348 Louvain-la-Neuve (BE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PROGNOSTIC METHODS FOR CONGESTIVE HEART FAILURE

Patients with severe CHF (NYHA Class III-IV)
A: Big-ET-1 (1-38) <4.0 pg/ml AND N-proANP (1-98) <6483 fmol/ml
B: Big-ET-1 (1-38) >4.0 pg/ml OR N-proANP (1-98) >6483 fmol/ml
C: Big-ET-1 (1-38) >4.0 pg/ml AND N-proANP (1-98) >6483 fmol/ml



(57) Abstract: Provided are methods for predicting survival outcome of an individual suffering from congestive heart failure. In accordance with the method, a patient's survival outcome is determined by taking into consideration the levels of two markers in combination, the combination being more predictive of survival than either marker alone. The markers include endothelin, atrial natriuretic peptide and brain natriuretic peptide, their precursors and fragments thereof. Individuals with congestive heart failure identified as having increased risk of mortality using the methods of the invention are appropriately targeted for more aggressive therapy.





WO 2005/089045 A2



Published:

 without international search report and to be republished upon receipt of that report For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.